Schizophrenia drug discovery and development in an evolving era: Are new drug targets fulfilling expectations?

Emerging Biology of PDE10A

(2014) Lindsay Wilson et al.   CURRENT PHARMACEUTICAL DESIGN

In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: 18F-MNI-659 and 18F-MNI-654

(2014) O. Barret et al.   JOURNAL OF NUCLEAR MEDICINE

Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human

(2014) C. Plisson et al.   JOURNAL OF NUCLEAR MEDICINE

Normalizing Effects of EVP-6124, an Alpha-7 Nicotinic Partial Agonist, on Event-Related Potentials and Cognition

(2014) SHELDON H. PRESKORN et al.   Journal of Psychiatric Practice

De novo mutations in schizophrenia implicate synaptic networks

(2014) Menachem Fromer et al.   NATURE

A polygenic burden of rare disruptive mutations in schizophrenia

(2014) Shaun M. Purcell et al.   NATURE

Biological insights from 108 schizophrenia-associated genetic loci

(2014)   NATURE

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

(2014) David Cook et al.   NATURE REVIEWS DRUG DISCOVERY

Advances in targeting cyclic nucleotide phosphodiesterases

(2014) Donald H. Maurice et al.   NATURE REVIEWS DRUG DISCOVERY

The Phosphodiesterase 10 Positron Emission Tomography Tracer, [18F]MNI-659, as a Novel Biomarker for Early Huntington Disease

(2014) David S. Russell et al.   JAMA Neurology

Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia

(2014) Daniel Umbricht et al.   JAMA Psychiatry

Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function

(2013) Arsime Demjaha et al.   BIOLOGICAL PSYCHIATRY

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

(2013) David H Adams et al.   BMC Psychiatry

PET imaging shows loss of striatal PDE10A in patients with Huntington disease

(2013) R. Ahmad et al.   NEUROLOGY

Phosphodiesterase 10A inhibitor MP-10 effects in primates: Comparison with risperidone and mechanistic implications

(2013) Subramaniam Uthayathas et al.   NEUROPHARMACOLOGY

Panel and Study Groups

(2013)   NEUROPSYCHOPHARMACOLOGY

Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model

(2013) Carina J. Bleickardt et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo

(2013) Virginia L. Stauffer et al.   SCHIZOPHRENIA RESEARCH

Impaired GABAergic Neurotransmission in Schizophrenia Underlies Impairments in Cortical Gamma Band Oscillations

(2013) James M. McNally et al.   Current Psychiatry Reports

Update on Typical and Atypical Antipsychotic Drugs

(2012) Herbert Y. Meltzer   Annual Review of Medicine

Synaptic and Extrasynaptic NMDA Receptors Are Gated by Different Endogenous Coagonists

(2012) Thomas Papouin et al.   CELL

Phosphodiesterase 10A inhibitors: a 2009 – 2012 patent update

(2012) Jan Kehler   EXPERT OPINION ON THERAPEUTIC PATENTS

A Multicenter, Add-On Randomized Controlled Trial of Low-Dosed-Serine for Negative and Cognitive Symptoms of Schizophrenia

(2012) Mark Weiser et al.   JOURNAL OF CLINICAL PSYCHIATRY

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity

(2012) Mitsumasa Kurita et al.   NATURE NEUROSCIENCE

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey

(2012) Sean M. Smith et al.   NEUROPHARMACOLOGY

Glycine Transporter Type 1 Occupancy by Bitopertin: a Positron Emission Tomography Study in Healthy Volunteers

(2012) Meret Martin-Facklam et al.   NEUROPSYCHOPHARMACOLOGY

Capturing the Angel in "Angel Dust": Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans

(2012) B. Moghaddam et al.   SCHIZOPHRENIA BULLETIN

NMDA Receptor Hypofunction, Parvalbumin-Positive Neurons, and Cortical Gamma Oscillations in Schizophrenia

(2012) G. Gonzalez-Burgos et al.   SCHIZOPHRENIA BULLETIN

Poster #212 RESULTS OF A PHASE 2A PROOF-OF-CONCEPT TRIAL WITH A PDE10A INHIBITOR IN THE TREATMENT OF ACUTE EXACERBATION OF SCHIZOPHRENIA

(2012) Nicholas DeMartinis et al.   SCHIZOPHRENIA RESEARCH

PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia

(2011) Jan Kehler et al.   CURRENT PHARMACEUTICAL DESIGN

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

(2011) Bruce J. Kinon et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

(2011) Matthew J. Fell et al.   NEUROPHARMACOLOGY

Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia

(2011) Daniela Alberati et al.   NEUROPHARMACOLOGY

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors

(2011) Jos Prickaerts et al.   NEUROPHARMACOLOGY

Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies

(2011) Anouk Marsman et al.   SCHIZOPHRENIA BULLETIN

Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists

(2010) John H. Krystal et al.   CNS DRUGS

Targeting α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia

(2010) Mihaly Hajos et al.   CURRENT PHARMACEUTICAL DESIGN

Neuronal Nicotinic Acetylcholine Receptors - Targets for the Development of Drugs to Treat Cognitive Impairment Associated with Schizophrenia and Alzheimers Disease

(2010) Simon Haydar et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Animal models of neuropsychiatric disorders

(2010) Eric J Nestler et al.   NATURE NEUROSCIENCE

Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia

(2010) W Liu et al.   PHARMACOGENOMICS JOURNAL

Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia

(2009) S. M. Grauer et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The neurobiology of D-amino acid oxidase and its involvement in schizophrenia

(2009) L Verrall et al.   MOLECULAR PSYCHIATRY

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

(2008) C. J. Schmidt et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)

(2008) M. J. Fell et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS